New modalities for the treatment of acute cardioembolic stroke

Internal Medicine

Volumn 45, Issue 8, 2006, Pages 493-494

  Uchiyama, Shinichiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Edaraucne; Froe radical; Ischemic penumbra; Neuroprotecion; Thrombolysis; Tissue plasminogen activator

Indexed keywords

NEUROPROTECTIVE AGENT; NORPHENAZONE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN PERFUSION; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; EDITORIAL; EMBOLISM; FIBRINOLYTIC THERAPY; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REPERFUSION;

ANTIPYRINE; AVULAVIRUS; FREE RADICAL SCAVENGERS; HUMANS; INTRACRANIAL EMBOLISM; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33646771391     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.0146     Document Type: Editorial

References (13)

1. Kimura K, Kazui S, Minematsu K, Yamaguchi T for the Japan Multicenter Stroke Investigator's Collaboration. Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 18: 47-56, 2004.
2. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 43: 71-84, 1986.
3. Kobayashi S. Stroke Data Bank 2005. Nakayama Shoten, Tokyo, 2005.
4. Furie KL, Homma S, Kistler JP. Cardiac diseases. in: Stroke: Pathophysiology, Diagnosis, and Management. 4th ed. Churchill Livingstone, New York, 2004: 747-759.
5. Gladstone DJ, Black SE, Hakim AM. Heart and Stroke Foundation of Ontario Center of excellence in Stroke Recovery: Toward wisdom from failure: Lesson from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-2136, 2002.
6. Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15: 222-229, 2003.
7. Inatori Y, Takita T, Yonehara T, Fujioka S, Hashimoto Y, Hirano T, Uchino M. Efficacy of edaravone in cardioembolic stroke. Intern Med 45: 253-257, 2006.
8. Uchiyama S, Yamazaki M, Hara Y, Iwata M. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin. Thromb. Hemost 23: 535-541, 1997.
9. American Academy of Emergency Medicine Work Group on Thrombolytic Therapy in Stroke. Position statement of the American Academy of Emergency Medicine on the treatment of stroke. www.aaem.org/ positionstatements/thrombolytictherapy.shtml. January. 21, 2002.
10. Jin YJ, Mima T, Raicu V, Park KC, Shimizu K. Combined argatroban and edaravon caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res 43: 75-79, 2002.
11. Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A. Effect of MCI-186 on brain edema in rats. Stroke 20: 1236-1240, 1989.
12. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4: 228-231, 1998.
13. Traynelis SF, Lipton SA. Is tissue plasminogen activator a threat to neurons? Nat Med 7: 17-18, 2001.